On September 23, 2020 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, reported that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for the use of the ThinPrep Pap Test PreservCyt Solution vial as an approved sample type for its BD Onclarity HPV Assay (Press release, BD Pharmaceutical Systems, SEP 23, 2020, View Source [SID1234565541]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The BD Onclarity Assay PMA supplement was submitted to the FDA to expand sample claims and platform usage. Pictured BD Onclarity HPV Assay reagent plates.
The BD Onclarity Assay PMA supplement was submitted to the FDA to expand sample claims and platform usage. Pictured BD Onclarity HPV Assay reagent plates.
The PMA supplement would expand the sample claims that can be used in addition to the BD SurePath vial for the detection of human papillomavirus (HPV) using the BD Onclarity HPV Assay. The submission includes performance data for the BD Viper LT and the BD COR Systems. An additional supplement was submitted in January 2020 to seek approval for the BD Onclarity HPV assay on the BD COR System and the BD SurePath Liquid Based Cytology vial.

BD recently announced the FDA approval of a PMA supplement that included the expansion for genotype reporting beyond HPV genotypes 16, 18, and 45 to include types 31, 51, 52, 33/58, 35/39/68, and 56/59/66 making the BD Onclarity HPV Assay the only FDA-approved assay to individually identify and report these genotype results.

"This PMA supplement to the FDA signifies BD’s commitment to expanding the availability of the BD Onclarity HPV Assay in the U.S. to support better patient management by providing clinicians more data to inform treatment decisions across multiple collection devices," said Dave Hickey, president of Integrated Diagnostic Solutions for BD. "BD is dedicated to providing comprehensive screening solutions that are accessible globally in the fight to eliminate cervical cancer."

About BD Onclarity HPV Assay
The BD Onclarity HPV Assay detects and identifies 14 high-risk human papillomavirus (HPV) types in a single analysis and provides genotyping information from specimens collected for cervical cancer screening purposes in the BD SurePath Collection Vial and in the Hologic PreservCyt Solution (not approved in the United States). The assay is for use in accordance with clinical guidelines and within the scope of local regulatory authorizations as part of a comprehensive approach to cervical cancer screening. The BD Onclarity HPV Assay has FDA approval for clinical use in cytology-based screening with ASC-US triage, in co-testing paradigm, and in primary HPV screening. BD Onclarity HPV Assay has FDA approval for use in vaccinated women. As the previously vaccinated subpopulation ages, the screening population will progressively include women with reduced prevalence of HPV 16 and 18, increasing the value of extended genotype reporting in a mixed population of vaccinated and unvaccinated women.7